Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

@article{Karron1996EvaluationOA,
  title={Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.},
  author={Ruth A. Karron and M K Makhene and Kathryn Gay and Michael H. Wilson and Mary Lou Clements and Brian R. Murphy},
  journal={The Pediatric infectious disease journal},
  year={1996},
  volume={15 8},
  pages={650-4}
}
BACKGROUND A safe and effective parainfluenza type 3 (PIV-3) virus vaccine is needed to prevent serious PIV-3-associated illness in infants younger than 6 months of age. In previous studies a live bovine PIV-3 (BPIV-3) vaccine, which was developed to prevent human PIV-3 (HPIV-3) disease, was shown to be safe, infectious, immunogenic and phenotypically stable in 6- to 36-month-old infants and children. METHODS The safety, infectivity and immunogenicity of a single dose of the BPIV-3 vaccine… CONTINUE READING